Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: The results of the Canadian national hereditary kidney cancer needs assessment survey

被引:6
作者
Violette, Philippe D. [1 ]
Kamel-Reid, Suzanne [2 ]
Graham, Gail E. [3 ,4 ]
Reaume, M. Neil [4 ,5 ]
Jewett, Michael A. [6 ]
Care, Melanie [7 ]
Basiuk, Joan [8 ]
Pautler, Stephen E. [1 ,9 ]
机构
[1] Univ Western Ontario, Schulich Sch Med & Dent, Dept Surg, Div Urol, London, ON, Canada
[2] Univ Hlth Network, Dept Pathol, Toronto, ON, Canada
[3] Childrens Hosp Eastern Ontario, Eastern Ontario Reg Genet Program, Ottawa, ON K1H 8L1, Canada
[4] Univ Ottawa, Ottawa, ON, Canada
[5] Ottawa Hosp Canc Ctr, Div Med Oncol, Ottawa, ON, Canada
[6] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Dept Surg Oncol, Toronto, ON, Canada
[7] Univ Hlth Network, Dept Mol Genet, Toronto, ON, Canada
[8] Kidney Canc Res Network Canada, Toronto, ON, Canada
[9] Univ Western Ontario, Schulich Sch Med & Dent, Dept Oncol, Div Surg Oncol, London, ON, Canada
来源
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2014年 / 8卷 / 11-12期
关键词
HIPPEL-LINDAU DISEASE; PERSONALIZED MEDICINE; BARRIERS; HETEROGENEITY; CARCINOMA;
D O I
10.5489/cuaj.2415
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Treatment of hereditary renal cell carcinoma (HRCC) requires a multidisciplinary approach that may involve medical oncologists, geneticists, genetic counsellors, and urologists. The objective of our survey was to obtain current and representative information about the use and perceived importance of genetic testing for HRCC in Canada. Methods: A self-administered web-based survey was provided to Canadian medical oncologists, geneticists, genetic counsellors, and urologists in collaboration with their respective associations. The survey was created through an iterative process in consultation with the Kidney Cancer Research Network of Canada and contained both quantitative and qualitative components. The survey was designed to be exploratory and results were compared across regions. Results: The overall response was low (6.6%). Of the respondents, 42%, 33%, 19%, 5% were genetic counsellors, urologists, medical oncologists and medical geneticists, respectively. Of the respondents, 62.7% described their practice as academic, and 37.3% described it as non-academic. Non-academic respondents tended to refer for genetic counselling less frequently than academic (48.6% vs. 67.2%). Most respondents believed that genetic testing for HRCC was available (82.8%), although 47.7% did not know which tests were available. This observation was consistent across provinces. Testing for Von Hippel-Lindau syndrome was given the highest priority among respondents. Limited provider knowledge, clinical guidelines, institutional funding, access, and poor coordination between disciplines were cited as barriers to testing. Interpretation: There is a need to increase provider knowledge of genetic testing for HRCC. These findings support the development of practice guidelines and national strategies to improve coordination of specialists and access to genetics services. Limitations of the present study include low survey response which did not allow for inferential analysis by geographic region or respondent specialty.
引用
收藏
页码:E832 / E840
页数:9
相关论文
共 33 条
  • [1] Technology assessment and resource allocation for predictive genetic testing: A study of the perspectives of Canadian genetic health care providers
    Adair, Alethea
    Hyde-Lay, Robyn
    Einsiedel, Edna
    Caulfield, Timothy
    [J]. BMC MEDICAL ETHICS, 2009, 10
  • [2] [Anonymous], 2013, CAN CANC STAT 2013
  • [3] Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine
    Audenet, Francois
    Yates, David R.
    Cancel-Tassin, Geraldine
    Cussenot, Olivier
    Roupret, Morgan
    [J]. BJU INTERNATIONAL, 2012, 109 (12) : 1864 - 1870
  • [4] Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine
    Bonter, Katherine
    Desjardins, Clarissa
    Currier, Nathan
    Pun, Jason
    Ashbury, Fredrick D.
    [J]. BMJ OPEN, 2011, 1 (01):
  • [5] Bradley S, 2009, CUAJ-CAN UROL ASSOC, V3, P32
  • [6] Genetic Testing by Cancer Site Urinary Tract
    Chan-Smutko, Gayun
    [J]. CANCER JOURNAL, 2012, 18 (04) : 343 - 349
  • [7] Hereditary and familial kidney cancer
    Coleman, Jonathan A.
    Russo, Paul
    [J]. CURRENT OPINION IN UROLOGY, 2009, 19 (05) : 478 - 485
  • [8] Familial and Hereditary Renal Cancer Syndromes
    Coleman, Jonathan A.
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2008, 35 (04) : 563 - 572
  • [9] Integrating molecular medicine into the US health-care system: Opportunities, barriers, and policy challenges
    Deverka, P. A.
    Doksum, T.
    Carlson, R. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (04) : 427 - 434
  • [10] Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
    Gerlinger, Marco
    Rowan, Andrew J.
    Horswell, Stuart
    Larkin, James
    Endesfelder, David
    Gronroos, Eva
    Martinez, Pierre
    Matthews, Nicholas
    Stewart, Aengus
    Tarpey, Patrick
    Varela, Ignacio
    Phillimore, Benjamin
    Begum, Sharmin
    McDonald, Neil Q.
    Butler, Adam
    Jones, David
    Raine, Keiran
    Latimer, Calli
    Santos, Claudio R.
    Nohadani, Mahrokh
    Eklund, Aron C.
    Spencer-Dene, Bradley
    Clark, Graham
    Pickering, Lisa
    Stamp, Gordon
    Gore, Martin
    Szallasi, Zoltan
    Downward, Julian
    Futreal, P. Andrew
    Swanton, Charles
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) : 883 - 892